Also known as Zetia and Ezetrol.
Data show early LDL‑C lowering with Repatha reduces major cardiovascular events and is cost‑effective for high‑risk patients without prior heart attack or stroke.
Real‑world analysis of 544,103 adults with ASCVD followed up to four years; comparative non‑statin outcomes evidence to inform treatment choices and LDL‑C goal attainment.
Pre‑specified VESALIUS‑CV analysis shows evolocumab plus background therapy lowers deaths and major CV events in high‑risk adults without prior MI/stroke.
VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.